1. Shen, Yong, Tang, Kejun, Chen, Dongdong, Qian, Jing, Du, Yushen. . Riok3 inhibits the antiviral immune response by facilitating TRIM40-mediated RIG-I and MDA5 degradation. In Cell reports, 35, 109272. doi:10.1016/j.celrep.2021.109272. https://pubmed.ncbi.nlm.nih.gov/34161773/
2. Zong, He-Xiang, Liu, Ya-Qian, Wang, Xi-le, Zhao, Xu, Xu, Sheng-Qian. 2023. RIOK3 potentially regulates osteogenesis-related pathways in ankylosing spondylitis and the differentiation of bone marrow mesenchymal stem cells. In Genomics, 115, 110730. doi:10.1016/j.ygeno.2023.110730. https://pubmed.ncbi.nlm.nih.gov/37866658/
3. Li, Jian, Sun, Ruili, He, Lixiang, Zhang, Jinghang, Ren, Feng. 2022. A systematic pan-cancer analysis identifies RIOK3 as an immunological and prognostic biomarker. In American journal of translational research, 14, 3750-3768. doi:. https://pubmed.ncbi.nlm.nih.gov/35836879/
4. Huang, Zixuan, Diehl, Frances F, Wang, Mengjiao, Green, Rachel, Cheng, Jingdong. 2025. RIOK3 mediates the degradation of 40S ribosomes. In Molecular cell, 85, 802-814.e12. doi:10.1016/j.molcel.2025.01.013. https://pubmed.ncbi.nlm.nih.gov/39947183/
智鼠故事 
